

Legacy Laboratory Services

Legacy Lab Alert

May 2019

An Important Update from Legacy Laboratory Services

Update: Ciprofloxacin & Levofloxacin Breakpoints

Effective May 29, 2019, Legacy Laboratory Services will change the breakpoints for reporting Ciprofloxacin and Levofloxacin for *Enterobacteriaceae* and *Pseudomonas aeruginosa*. Current reporting for these antibiotics is based on FDA breakpoints. The updated breakpoints are based on 2019 CLSI (Clinical and Laboratory Standards Institute) breakpoints. The new breakpoints are lower and may show more resistance for these antibiotics. CLSI lowered the breakpoints after finding low probability of treatment success for the sickest patients with the FDA breakpoints.

	CURRENT (Prior to 5/29/19)			NEW (Starts 5/29/19)		
	Old MIC Guidelines (µg/mL)			New MIC Guidelines (µg/mL)		
<i>Enterobacteriaceae</i> *	S	I	R	S	I	R
Ciprofloxacin	≤1	2	≥4	≤0.25	0.5	≥1
Levofloxacin	≤2	4	≥8	≤0.5	1	≥2
<i>Pseudomonas aeruginosa</i>						
Ciprofloxacin	≤1	2	≥4	≤0.5	1	≥2
Levofloxacin	≤2	4	≥8	≤1	2	≥4

*Update for *Enterobacteriaceae* other than *Salmonella* spp.

Reference: Performance Standards for Antimicrobial Susceptibility Testing, 29th Edition, M100. Clinical and Laboratory Standards Institute, Wayne, PA 19087 USA, 1/2019.

For additional information, please contact your account representative, client services or consult our website:
Legacy Laboratory Client Services: 503-413-1234, 877-270-5566, www.legacyhealth.org/labservices